Antylia Scientific creates 60 manufacturing jobs in Midlands

Antylia Scientific creates 60 roles in the Midlands with establishment of new state-of-the-art manufacturing facility.

US-headquartered life sciences manufacturer Antylia Scientific is to create 60 new jobs in Westmeath with the establishment of its Masterflex Bioprocessing facility at the National Science Park in Mullingar.

Antylia Scientific is a global leader in peristaltic and associated fluid path products providing bioprocessing solutions, and a diverse portfolio of life sciences and diagnostic products for the pharma, biopharma, healthcare, and environmental markets.

“It is a win-win situation that will positively benefit our customers, our Masterflex brand, and the Mullingar workforce and economy”

This project is supported by the Irish Government through IDA Ireland.

Mission critical products

The new Masterflex Bioprocessing facility will be used to design and manufacture Masterflex peristaltic technologies that are used in mission-critical pharmaceutical and bioprocessing workflows for the development and production of vaccines and therapeutics. The facility will also include a large warehouse space to store components and the finished products.

“We are grateful to the Irish Government through IDA Ireland for this tremendous opportunity,” said Brian Barnett, president of Masterflex Bioprocessing. “We are thrilled to open our first facility in Ireland to produce and house Masterflex peristaltic technologies and associated fluid path products. These products are in great demand globally.

“The addition of this site to our Masterflex Bioprocessing family of global sites providing mission critical products and services will help the overall Biopharma industry. It is a win-win situation that will positively benefit our customers, our Masterflex brand, and the Mullingar workforce and economy.”

The jobs being created at the new Masterflex Bioprocessing facility in Mullingar are in the areas of process and medical device engineering, manufacturing as well as logistics and supply chain.

This investment by Antylia Scientific and the IDA in the new Masterflex Bioprocessing facility will expand access to these critical fluid path products and provide customers with shorter lead times, simplified sourcing and validation and increased supply for these critical fluid path products.

“Today’s announcement by Antylia Scientific is a very positive one for the Midlands and is a strong endorsement in the region’s talented and highly skilled Biopharma and MedTech workforce,” said IDA Ireland CEO Martin Shanahan.

“Antylia Scientific’s significant investment in its Mullingar facility based at the National Science Park demonstrates the company’s commitment to the Midlands region.  I wish Antylia every success with this investment.”

By John Kennedy (john.kennedy3@boi.com)

Published: 6 May 2021

Recommended